CSE AIML | OTCQB AIMLF | FWB 42FB
PRESS RELEASE

AIML Announces SEDAR Filing

August 21, 2025

Vancouver, Canada – August 21, 2025 – AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) is issuing the following press release to clarify its disclosure as a result of a review by the British Columbia Securities Commission. The Company announces today that it has filed an amended and restated management's discussion and analysis for the three and nine month periods ended January 31, 2025 (the "Amended MD&A") in order to rectify certain disclosure deficiencies, including:

● to provide enhanced disclosure relating to (i) new strategic initiatives and R&D activities of the Company; (ii) the results of operations of the Company for the three and nine month periods ended January 31, 2025; and (iii) the acquisitions by the Company of Quantum Sciences Ltd. and certain other intangible assets and associated intellectual property during the period;

● to incorporate additional details regarding payments made to related parties during the period;

● to include a discussion of the exit agreement with Tech2Heal; and

● to incorporate other minor housekeeping changes.

The Amended MD&A is available on SEDAR+ at www.sedarplus.ca.

For more information about AIML:

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact:
Blake Fallis
(778) 405-0882
info@aiml.health

About AIML Innovations Inc.
https://www.aiml.health/

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights - supporting earlier diagnosis, personalized treatment, and more effective care. AIML’s shares trade on the Canadian Securities Exchange (CSE: AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

On behalf of the Board of Directors:
Paul Duffy, Chairman

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements – Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Such statements remain subject to various risks, including risks relating to the proposed future operations of the Company, availability of funding, industry developments and competition. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company disclaims any obligation to update such forward looking statements other than as required by law.

Read More

September 4, 2025
AIML Announces Proposed Private Placement
Read More
August 21, 2025
AIML Announces SEDAR Filing
Read More
August 8, 2025
AIML Innovations Closes Quantum Sciences Ltd. Restructuring
Read More
June 10, 2025
AIML Strengthens IP Portfolio with Provisional Patents for AI Driven ECG Signal Processing
Read More
June 3, 2025
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield™ ECG Signal-Processing
Read More
May 22, 2025
AIML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
Read More
May 20, 2025
AIML Establishes Medical Advisory Board to Drive AI Powered ECG Signal Processing Innovation
Read More
May 15, 2025
AIML Hits Key Regulatory Benchmark with 510(k) Filing for MaxYield™ Signal Enhancement Platform
Read More
May 5, 2025
AIML Innovations Appoints Political Strategist and Public Affairs Leader, Michael Diamond, to Board of Directors
Read More
April 25, 2025
AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Read More
April 25, 2025
AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Read More
April 22, 2025
AIML Innovations Appoints Jared Adelstein to Board of Directors
Read More
April 15, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
April 7, 2025
AIML Updates Terms of Proposed Private Placement Announced
Read More
April 4, 2025
AIML Announces Proposed Private Placement
Read More
January 9, 2025
AI/ML Innovations Inc. Welcomes Industry Trailblazers to Board of Directors
Read More
January 23, 2025
AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships
Read More
January 28, 2025
Andrea Ruth Joins AI/ML Innovations as Head of Quality, Clinical, and Regulatory Affairs
Read More
February 20, 2025
Key Updates to Upcoming Annual and Special Meeting
Read More
March 14, 2025
AIML Aligns Leadership for Growth and Shareholder Value Creation
Read More
March 21, 2025
AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
Read More